EKOS is a safe, repeatable and reliable treatment that dissolves thrombus quickly with low lytic, low blood loss and low trauma – resulting in proven long-term outcomes. EKOS leverages the power of targeted ultrasonic waves to thin and separate fibrin strands and accelerates lytic dispersion deeper into the clot.

Tailor-made for treating pulmonary embolism, EKOS+ provides more ultrasound power to resolve clot burden more quickly and completely without any required changes to lytic dose, treatment duration, or current clinical practice.

2022年8月12日 · One such catheter-based treatment known as “ultrasound-assisted thrombolysis” (UAT) involves the EKOS™ Catheter, a device that’s designed to: (1) deliver a clot-busting drug to dissolve existing clots; and (2) use energy from sound waves to spread the drug out within the clot.

In this article we will review catheter-directed thrombolytic therapy, specifically the EKOS® or the EkoSonic endovascular system. EKOS® uses ultrasound-facilitated catheter-directed thrombolysis.

The EKOS system uses ultrasound energy to accelerate dispersion of clot-busting lytic agents deep into the thromboembolism, 1,2 reducing the total dose of lytic drug by up to 92% compared to standard systemic lytic treatment. 3,4 Ultrasound pressure waves and acoustic streaming actively drive lytic into the clot, loosen the fibrin strands ...

The EkoSonic Endovascular System, EKOS, is a catheter-directed thrombolysis system which uses ultrasound to treat blood clots. The EKOS system was approved by the FDA in 2004 and is used to treat PE, DVT, and arterial occlusion. The EKOS Catheter has been evaluated for the treatment of severe PE (patients at imminent risk of death).

Catheter-Directed Thrombolysis (EKOS) uses a combination of drugs and ultrasound waves to break up or dissolve major blood clots that cause pulmonary embolism. Using the EKOS EndoWave Infusion Catheter System®, Temple interventionists can restore blood flow and limit damage to the patient’s lungs, and potentially heart or brain.

With 50% more ultrasound power, the new EKOS+ catheter builds on the EKOS legacy and provides physicians more confidence to efficiently treat PE patients with lower lytic doses.

ultrasound-facilitated catheter-directed thrombolysis (USCDT). THE EKOS PLATFORM: EKOS AND EKOS+ ENDOVASCULAR SYSTEMS USCDT via the EKOS™ Endovascular System (EKOS; Boston Scientific Corporation) has been the default approach within our practice for many years. The procedure is technically straightforward and the out-

The EKOS ™ Endovascular System is used in treatment of Pulmonary Embolism (PE) using ultrasound-accelerated, catheter-directed thrombolysis to safely dissolve thrombus quickly with low lytic, low blood loss and low trauma.